Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

British consumers and businesses are cautioned against buying sweets from US brand Hershey as they are "unsafe to eat," ...

McDonald’s shares have now been cut by analysts three times in as many trading days, with the latest “buy-to-sell” slap from ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

As medications like Ozempic transform the health of millions of Americans, some families are discovering a surprising side ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Officials at the FDA say they want to speed up approvals for new drugs and devices using tech like the new "Elsa" AI system. More news is on other uses of AI in health care, Eli Lilly refusing to work ...

Losing weight and sustaining a healthy weight are notoriously difficult. If you’re struggling to reach your weight goals, you ...